CPE Media News | July 4, 2018
CPE Media News – pcJournal (7/4/2018) – MetaOptima Technology Inc. has raised US $6.5 million recently from Australian venture firms, Skip Capital and AirTree Ventures.
Scott Farquhar and Kim Jackson of Skip Capital, and Daniel Petre of AirTree Ventures, have joined MetaOptima Technology board of directors.
Founded in 2012 by CEO Maryam Sadeghi, Ph.D., and CTO Majid Razmara, Ph.D., MetaOptima Technology Inc. is a developer of intelligent dermoscopy tools for smart skin imaging, analytics, management, and skin cancer early detection.
photo credit: MetaOptima Technology
Partnering With Skip Capital and AirTree To Develop Intelligent Dermatology Tools
Posted by The DermEngine Team on Jun 5, 2018 3:01:23 PM
The MetaOptima Team is thrilled to announce that Skip Capital and AirTree Ventures have invested $US 6.5 million in our company to support our continued journey of creating and developing intelligent dermoscopy tools for smart skin imaging, analytics, management, and skin cancer early detection! This news is an incredible opportunity for MetaOptima, and the entire team is thrilled to work alongside, Scott Farquhar, Kim Jackson and Daniel Petre during this revolutionary time for digital healthcare.
DermEngine: The World’s Most Intelligent Dermatology Software
DermEngine is a proprietary cloud-based platform for dermoscopy and skin care that serves patients, physicians and service providers. Powered by big data, this intelligent dermatology software is equipped with advanced deep-learning algorithms, sophisticated analytics and intuitive, user-friendly image archiving and management capabilities.
The secure platform offers clinical decision support tools powered by content-based image retrieval (CBIR) algorithms. These advanced algorithms are designed to retrieve visually similar images from thousands of pathology-labelled images to a dermoscopic picture submitted by the medical professional. This tool supports the dermatologist in providing feedback and is a powerful educational resource for enhancing clinical decisions.